Company intelligence / Profile preview

Interferon Sciences, Inc.

New Brunswick, New Jersey, United Statesprofiles.biocentury.com ↗

Ownership: Private
Development stage: Commercial

Overview

Interferon Sciences developed and commercialized Alferon N Injection®, a natural-source alpha interferon product approved by the FDA for the treatment of certain types of genital warts. The company attempted to expand into additional indications such as hepatitis C and HIV but was unable to complete required clinical studies due to limited financial resources. As a result, its pipeline did not advance beyond early clinical or regulatory stages for these new uses.

Therapeutic areas: Infectious Diseases
Modalities: Protein therapeutics (natural-source alpha interferons)Cytokines
Industry: Biotech

Drug pipeline

3 assets

interferon alpha-2b

Commercial

Indications: Hepatitis B, Hepatitis C, Cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Interferon Sciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interferon Sciences, Inc..

Explore the full profile